Embolization in pelvic venous disorders using ethylene vinyl alcohol copolymer (Onyx®) and Aetoxysclerol: a prospective evaluation of safety and long-term efficacy

• Published in: European radiology 2022-07, Vol.32 (7), p.4679-4686
• Main Authors: Jambon, E., Le Bras, Y., Coussy, A., Petitpierre, F., Hans, H., Lasserre, A., Cazalas, G., Grenier, N., Marcelin, C.
• Format: Article
• Language: English
• Subjects: Complications; Copolymers; Diagnostic Radiology; Disorders; Embolization; Ethylene; Evaluation; Imaging; Impairment; Internal Medicine; Interventional; Interventional Radiology; Magnetic resonance imaging; Medical imaging; Medicine; Medicine & Public Health; Menstruation; Neuroradiology; Pain; Patients; Psychology; Radiology; Safety; Ultrasound; Visualization
• ISSN: 1432-1084; 0938-7994; 1432-1084
• DOI: 10.1007/s00330-022-08567-z

Objectives To prospectively evaluate the safety and efficacy of embolization using ethylene vinyl alcohol copolymer (Onyx ® ) and Aetoxysclerol for treatment of pelvic venous disorders (PeVD). Methods This prospective study was approved by the institutional ethics review board. Ten clinical parameters were retained for evaluation of PeVD (pelvic pain, dyspareunia, post-coital pain, menstruation pain, lower limbs pain, difficulty walking, aesthetic discomfort, impact on daily working life, psychological impact and impact on daily life), measured on a visual analogue scale (VAS) between 0 and 10, and a global score out of 100 was noted before embolization, after 3 months during the imaging follow-up, and at the end of follow-up by phone call. The main criterion was clinical efficacy of embolization defined by an impairment score < 40/100 and a 50% decrease in overall score. Complications were recorded. Visualization of Onyx ® on MRI 3 months after embolization was noted. Results Between July 2017 and May 2019, 73 consecutive women (mean age ± SD [range]: 41 ± 11 years [25–77]) treated by embolization with Onyx ® and Aetoxysclerol were included. The median follow-up was 28 months [Q1–Q3: 24.0–29.2] (range: 18.1–34.5). The median initial VAS impairment score was 39/100 [29.75–48.50] (12–58). Clinical efficacy was obtained for 70 patients (70/73, 95.9%), and the median VAS impairment score at the end of follow-up was significantly lower at 3 [0.00–7.25] (0–73) ( p < 0.0001). Four minor complications occurred. Onyx ® was visualized on DIXON sequence of MRI for all patients. Conclusion Embolization using Onyx ® and Aetoxysclerol for PeVD is safe and effective. Key Points • Embolization using Onyx ® and Aetoxysclerol for pelvic venous disorders is safe and effective. • Imaging follow-up is facilitated by visualization of Onyx ® on MRI DIXON sequences.